hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia.

21. The process of claim **13** wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia.

22. The process of claim **14** wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia.

23. The process of claim **15** wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia.

24. The process of claim **16** wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia.

25. The process of claim **17** wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia.

26. The process of claim **18** wherein said subject exhibits type-II diabetes and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: decrease in insulin resistance, reduction of hyperinsulinemia, increase in glucose tolerance, reduction of triglyceride levels, and reduction of hyperglycemia.

27. The process of claim **11** wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia.

28. The process of claim **12** wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia.

29. The process of claim **13** wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia.

30. The process of claim **14** wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia.

31. The process of claim **15** wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia.

32. The process of claim **16** wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia.

33. The process of claim **17** wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia.

34. The process of claim **18** wherein said subject exhibits obesity and said dopamine agonist is administered to said in a dosage amount and for a period sufficient to achieve in said subject at least one of the following modifications: reduction in body fat stores, reduction of triglyceride levels, and reduction of hyperglycemia.

35. The process of claim **8** wherein said bromocriptine is given daily confined to a time or times ranging from about 0 hours to about 3 hours after awakening.

36. The process of claim **18** wherein said bromocriptine is given daily confined to a time or times ranging from about 0 hours to about 3 hours after awakening.

37. The process of claim **26** wherein said bromocriptine is given daily confined to a time or times ranging from about 0 hours to about 3 hours after awakening.

38. The process of claim **34** wherein said bromocriptine is given daily confined to a time or time ranging from about 0 hours to about 3 hours after awakening.

* * * * *